See more : The First Insurance Co., Ltd. (2852.TW) Income Statement Analysis – Financial Results
Complete financial analysis of CTI BioPharma Corp. (CTIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CTI BioPharma Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PlaySide Studios Limited (PLY.AX) Income Statement Analysis – Financial Results
- Cerro de Pasco Resources Inc. (GPPRF) Income Statement Analysis – Financial Results
- ORIC Pharmaceuticals, Inc. (ORIC) Income Statement Analysis – Financial Results
- Fast Retailing Co., Ltd. (6288.HK) Income Statement Analysis – Financial Results
- Hongkong Land Holdings Limited (H78.SI) Income Statement Analysis – Financial Results
CTI BioPharma Corp. (CTIC)
About CTI BioPharma Corp.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.95M | 0.00 | 0.00 | 3.35M | 26.29M | 25.15M | 57.41M | 16.12M | 60.08M | 34.68M | 0.00 | 0.00 | 319.00K | 80.00K | 11.43M | 127.00K | 80.00K | 16.09M | 29.59M | 24.77M | 16.90M | 6.24M | 502.04K | 100.00K | 13.20M | 11.80M | 9.10M |
| Cost of Revenue | 3.51M | 161.00K | 4.20M | 0.00 | 879.00K | 364.00K | 1.38M | 1.94M | 895.00K | 137.00K | 0.00 | 0.00 | 0.00 | 0.00 | 3.24M | 49.00K | 0.00 | 518.00K | 1.10M | 840.00K | 423.00K | 394.00K | -1.02M | -2.20M | -1.90M | -1.60M | 14.30M |
| Gross Profit | 50.43M | -161.00K | -4.20M | 3.35M | 25.41M | 24.78M | 56.03M | 14.18M | 59.18M | 34.54M | 0.00 | 0.00 | 319.00K | 80.00K | 8.19M | 78.00K | 80.00K | 15.57M | 28.49M | 23.93M | 16.47M | 5.84M | 1.53M | 2.30M | 15.10M | 13.40M | -5.20M |
| Gross Profit Ratio | 93.49% | 0.00% | 0.00% | 100.00% | 96.66% | 98.55% | 97.60% | 87.96% | 98.51% | 99.60% | 0.00% | 0.00% | 100.00% | 100.00% | 71.62% | 61.42% | 100.00% | 96.78% | 96.27% | 96.61% | 97.50% | 93.68% | 304.14% | 2,300.00% | 114.39% | 113.56% | -57.14% |
| Research & Development | 36.90M | 39.14M | 25.94M | 24.11M | 36.47M | 32.87M | 64.96M | 76.63M | 86.46M | 33.62M | 62.31M | 34.90M | 27.03M | 30.18M | 51.61M | 72.02M | 61.99M | 68.77M | 101.13M | 89.53M | 58.76M | 44.67M | 26.57M | 27.70M | 29.20M | 27.30M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 17.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 84.83M | 56.20M | 17.63M | 19.16M | 21.18M | 31.44M | 45.31M | 53.96M | 56.24M | 42.29M | 38.24M | 38.29M | 48.04M | 57.73M | 41.61M | 35.32M | 35.30M | 61.72M | 78.52M | 55.64M | 49.80M | 35.27M | 20.42M | 9.80M | 11.60M | 10.10M | 7.60M |
| Other Expenses | 8.51M | -161.00K | 4.20M | 1.32M | 0.00 | 0.00 | -5.08M | 253.00K | 2.72M | 155.00K | 30.05M | 0.00 | 0.00 | 0.00 | -7.79M | 913.00K | 792.00K | -69.96M | 2.29M | 1.34M | 6.70M | 9.39M | 10.43M | 2.20M | 1.90M | 1.60M | 1.80M |
| Operating Expenses | 130.23M | 95.33M | 47.77M | 43.26M | 57.65M | 64.30M | 105.19M | 130.84M | 145.42M | 75.91M | 100.55M | 73.19M | 75.07M | 87.90M | 85.44M | 108.25M | 98.09M | 60.53M | 181.94M | 146.51M | 115.26M | 89.33M | 57.43M | 39.70M | 42.70M | 39.00M | 9.40M |
| Cost & Expenses | 133.75M | 95.33M | 47.77M | 43.26M | 58.53M | 64.67M | 106.57M | 132.78M | 146.31M | 76.05M | 100.55M | 73.19M | 75.07M | 87.90M | 88.68M | 108.30M | 98.09M | 61.05M | 183.05M | 147.35M | 115.68M | 89.72M | 56.40M | 37.50M | 40.80M | 37.40M | 23.70M |
| Interest Income | 1.68M | 38.00K | 204.00K | 1.17M | 1.22M | 0.00 | -2.61M | -2.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.14M | 2.42M | 1.03M | 1.52M | 1.73M | 2.04M | 2.83M | 2.49M | 2.68M | 1.54M | 56.00K | 1.04M | 2.33M | 4.81M | 8.56M | 14.83M | 44.58M | 17.56M | 10.99M | 9.33M | 11.24M | 5.99M | 544.29K | 0.00 | 400.00K | 0.00 | 500.00K |
| Depreciation & Amortization | -56.00K | -161.00K | 204.00K | 3.29M | 593.00K | 717.00K | 831.00K | 990.00K | 1.10M | 1.57M | 2.35M | 2.41M | 1.84M | 1.77M | 5.23M | 4.69M | 6.50M | 10.28M | 11.43M | 8.44M | 14.24M | 12.24M | 10.43M | 2.20M | 1.90M | 1.60M | 1.80M |
| EBITDA | -79.85M | -95.33M | -47.77M | -37.43M | -32.90M | -39.52M | -49.16M | -116.67M | -86.23M | -39.63M | -98.97M | -58.91M | -74.76M | -81.56M | -77.28M | -132.99M | -98.60M | -57.73M | -229.88M | -112.27M | -98.79M | -62.05M | -40.95M | -34.10M | -22.70M | -21.40M | -11.60M |
| EBITDA Ratio | -148.02% | 0.00% | 0.00% | -1,118.83% | -102.67% | -150.79% | -84.23% | -719.40% | -149.13% | -114.29% | 0.00% | 0.00% | -24,597.49% | -111,022.50% | -1,454.18% | -93,375.59% | -105,916.25% | -464.01% | -776.77% | -453.32% | -144.55% | -995.00% | -8,156.98% | -34,100.00% | -171.97% | -181.36% | -127.47% |
| Operating Income | -79.80M | -95.33M | -47.77M | -40.71M | -32.90M | -39.52M | -49.16M | -116.67M | -86.23M | -41.53M | -101.50M | -62.19M | -74.76M | -81.56M | -77.28M | -132.99M | -98.60M | -57.73M | -240.83M | -122.59M | -98.79M | -83.49M | -55.90M | -37.40M | -27.60M | -25.60M | -14.60M |
| Operating Income Ratio | -147.91% | 0.00% | 0.00% | -1,217.07% | -125.14% | -157.16% | -85.64% | -723.91% | -143.54% | -119.75% | 0.00% | 0.00% | -23,434.17% | -101,948.75% | -676.02% | -104,713.39% | -123,250.00% | -358.77% | -813.77% | -494.99% | -584.68% | -1,338.76% | -11,134.98% | -37,400.00% | -209.09% | -216.95% | -160.44% |
| Total Other Income/Expenses | -13.20M | -2.58M | -4.68M | 688.00K | 3.55M | -1.31M | -3.79M | -4.10M | -8.00M | -2.02M | -190.00K | -429.00K | -20.64M | -13.84M | -102.75M | -5.12M | -37.22M | -44.77M | -11.47M | -7.45M | 48.88M | 9.20M | 4.52M | 1.70M | 3.00M | 2.90M | 1.20M |
| Income Before Tax | -92.99M | -97.91M | -52.45M | -40.02M | -29.35M | -40.83M | -52.95M | -120.76M | -94.23M | -43.55M | -101.69M | -62.62M | -95.40M | -95.40M | -180.03M | -138.11M | -135.82M | -102.51M | -252.30M | -130.03M | -49.90M | -74.29M | -51.38M | -35.70M | -24.60M | -22.70M | -13.40M |
| Income Before Tax Ratio | -172.37% | 0.00% | 0.00% | -1,196.50% | -111.65% | -162.38% | -92.24% | -749.34% | -156.85% | -125.58% | 0.00% | 0.00% | -29,904.39% | -119,243.75% | -1,574.78% | -108,746.46% | -169,773.75% | -636.99% | -852.53% | -525.06% | -295.35% | -1,191.23% | -10,235.12% | -35,700.00% | -186.36% | -192.37% | -147.25% |
| Income Tax Expense | -1.95M | 1.73M | 500.00K | 2.29M | 5.28M | 723.00K | -963.00K | -1.60M | -5.32M | -485.00K | -134.00K | 609.00K | -3.41M | 1.79M | -85.79M | -362.00K | 51.35M | 48.78M | -76.87M | 11.21M | 71.36M | 15.19M | 5.06M | 1.70M | 3.40M | 2.90M | 1.70M |
| Net Income | -91.04M | -99.64M | -52.95M | -42.32M | -29.32M | -40.67M | -52.01M | -119.42M | -93.37M | -42.74M | -101.37M | -62.36M | -82.64M | -95.40M | -180.03M | -138.11M | -135.82M | -102.51M | -252.30M | -130.03M | -49.90M | -80.27M | -51.93M | -36.30M | -25.00M | -23.00M | -13.90M |
| Net Income Ratio | -168.76% | 0.00% | 0.00% | -1,265.08% | -111.53% | -161.74% | -90.60% | -741.02% | -155.41% | -123.26% | 0.00% | 0.00% | -25,906.58% | -119,243.75% | -1,574.78% | -108,746.46% | -169,773.75% | -636.99% | -852.53% | -525.06% | -295.35% | -1,287.25% | -10,343.54% | -36,300.00% | -189.39% | -194.92% | -152.75% |
| EPS | -0.79 | -1.11 | -0.74 | -0.73 | -0.52 | -1.12 | -1.86 | -4.26 | -6.29 | -3.74 | -17.44 | -18.18 | -36.21 | -62.44 | -1.86K | -9.15K | -14.52K | -19.06K | -56.02K | -46.71K | -17.74K | -28.49K | -24.59K | -28.03K | -19.47K | -17.95K | -12.81K |
| EPS Diluted | -0.79 | -1.11 | -0.74 | -0.73 | -0.52 | -1.12 | -1.86 | -4.26 | -6.29 | -3.74 | -17.44 | -18.18 | -36.21 | -62.44 | -1.86K | -9.15K | -14.52K | -19.06K | -56.02K | -46.71K | -17.74K | -28.49K | -24.59K | -28.03K | -19.47K | -17.95K | -12.81K |
| Weighted Avg Shares Out | 114.69M | 90.12M | 71.14M | 57.97M | 56.07M | 36.45M | 27.95M | 28.05M | 14.85M | 11.42M | 5.81M | 3.43M | 2.28M | 1.53M | 96.56K | 15.10K | 9.36K | 5.38K | 4.50K | 2.78K | 2.81K | 2.82K | 2.11K | 1.30K | 1.28K | 1.28K | 1.09K |
| Weighted Avg Shares Out (Dil) | 114.69M | 90.12M | 71.14M | 57.97M | 56.07M | 36.45M | 27.95M | 28.05M | 14.85M | 11.42M | 5.81M | 3.43M | 2.28M | 1.53M | 96.56K | 15.10K | 9.36K | 5.38K | 4.50K | 2.78K | 2.81K | 2.82K | 2.11K | 1.30K | 1.28K | 1.28K | 1.09K |
Sobi completes acquisition of CTI BioPharma Corp.
STOCKHOLM , June 26, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) and CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) announced today the completion of the acquisition of CTI by Sobi through its indirect wholly owned subsidiary Cleopatra Acquisition Corp. (Cleopatra)....
Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE...
CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CTI BioPharma Corp. (NasdaqCM: CTIC) to Swedish Orphan Biovitrum AB ("Sobi")....
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
SEATTLE , May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting...
Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE...
CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CTI BioPharma Corp. (NasdaqCM: CTIC) to Swedish Orphan Biovitrum AB ("Sobi")....
CTI BioPharma skyrockets on acquisition by Sobi
CTI BioPharma shares added almost 85% on the news that the company would be acquired by Stockholm-based hematology and immunology leader Swedish Orphan Biovitrum AB (Sobi). Seattle-based CTI is a biopharmaceutical company focused on the development and commercialization of novel...
Why Shares of CTI BioPharma Are Soaring Wednesday
CTI BioPharma has one FDA-approved therapy, Vonjo, to treat a rare form of bone marrow cancer. The company is being bought at a 89% premium from its closing price on Tuesday.
Shareholder Alert: Ademi LLP investigates whether CTI BioPharma Corp. has obtained a Fair Price in its transaction with Sobi
MILWAUKEE , May 10, 2023 /PRNewswire/ -- Ademi LLP is investigating CTI BioPharma (Nasdaq: CTIC) for possible breaches of fiduciary duty and other violations of law in its transaction with Sobi. Click here to learn how to join the action https://www.ademilaw.com/case/cti-biopharma-corp...
U.S. stock futures climb as inflation continues to cool
U.S. stock index futures climbed on Wednesday after data showed U.S. consumer price inflation cooled to lowest annual rate in two years in April, though the core inflation, which excludes food and energy prices, remains stickier.
Source: https://incomestatements.info
Category: Stock Reports